Home
CLLS
CLLS News

Latest Cellectis S.A. (CLLS) News on November 17, 2024

Monthly information on share capital and company voting rights

GlobeNewswire

11 days ago

Monthly information on share capital and company voting rights

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

GlobeNewswire

12 days ago

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

GlobeNewswire

13 days ago

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings

GuruFocus.com

13 days ago

What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

GlobeNewswire

18 days ago

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Cellectis Presents New Gene-Editing Breakthroughs

TipRanks

25 days ago

Cellectis Presents New Gene-Editing Breakthroughs

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

GlobeNewswire

a month ago

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Monthly information on share capital and company voting rights

GlobeNewswire

2 months ago

Monthly information on share capital and company voting rights

CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?

Zacks

2 months ago

CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?

Monthly information on share capital and company voting rights

GlobeNewswire

2 months ago

Monthly information on share capital and company voting rights

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

GlobeNewswire

2 months ago

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

GlobeNewswire

3 months ago

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

GlobeNewswire

3 months ago

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Cellectis Provides Financial Results for the Second Quarter 2024

GlobeNewswire

3 months ago

Cellectis Provides Financial Results for the Second Quarter 2024

Monthly information on share capital and company voting rights

GlobeNewswire

3 months ago

Monthly information on share capital and company voting rights

Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia

Pharmaceutical Technology

3 months ago

Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

GlobeNewswire

4 months ago

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

GlobeNewswire

4 months ago

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?

Zacks

4 months ago

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?

Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

Zacks

4 months ago

Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)

Monthly information on share capital and company voting rights

GlobeNewswire

4 months ago

Monthly information on share capital and company voting rights

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

GlobeNewswire

5 months ago

Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

GlobeNewswire

5 months ago

Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

Cellectis (CLLS) Upgraded to Buy: Here's Why

Zacks

5 months ago

Cellectis (CLLS) Upgraded to Buy: Here's Why

After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)

Zacks

5 months ago

After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

GlobeNewswire

5 months ago

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Monthly information on share capital and company voting rights

GlobeNewswire

5 months ago

Monthly information on share capital and company voting rights

MT Newswires

5 months ago

Cellectis Gets Orphan Drug Label From European Commission For Acute Lymphoblastic Leukemia

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

GlobeNewswire

5 months ago

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

GlobeNewswire

6 months ago

Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

Cellectis Reports Financial Results for First Quarter 2024

GlobeNewswire

6 months ago

Cellectis Reports Financial Results for First Quarter 2024

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

GlobeNewswire

6 months ago

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

Monthly information on share capital and company voting rights

GlobeNewswire

6 months ago

Monthly information on share capital and company voting rights

AstraZeneca concludes equity investment in Cellectis

Pharmaceutical Technology

6 months ago

AstraZeneca concludes equity investment in Cellectis

Monthly information on share capital and company voting rights

GlobeNewswire

6 months ago

Monthly information on share capital and company voting rights

AstraZeneca ups stake in Cellectis in latest cell therapy bet

BioPharma Dive

6 months ago

AstraZeneca ups stake in Cellectis in latest cell therapy bet

MT Newswires

6 months ago

Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

GlobeNewswire

6 months ago

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

MT Newswires

6 months ago

Cellectis CFO Bing Wang Retires, Interim CFO Appointed

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

GlobeNewswire

7 months ago

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

GlobeNewswire

7 months ago

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

GlobeNewswire

7 months ago

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

GlobeNewswire

7 months ago

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

GlobeNewswire

7 months ago

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Monthly information on share capital and company voting rights

GlobeNewswire

7 months ago

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

GlobeNewswire

8 months ago

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

GlobeNewswire

9 months ago

Monthly information on share capital and company voting rights

LINKBANCORP, Inc. Announces Fourth Quarter 2023 and Full Year 2023 Financial Results

PR Newswire

10 months ago

LINKBANCORP, Inc. Announces Fourth Quarter 2023 and Full Year 2023 Financial Results

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

Barrons.com

10 months ago

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

Maxeon Solar Technologies Recognized as One of the World's Top 50 Most Sustainable Corporations

PR Newswire

10 months ago

Maxeon Solar Technologies Recognized as One of the World's Top 50 Most Sustainable Corporations

Hertz Global Holdings, Inc. (HTZ) Surges 7.5%: Is This an Indication of Further Gains?

Zacks

10 months ago

Hertz Global Holdings, Inc. (HTZ) Surges 7.5%: Is This an Indication of Further Gains?

Business Wire

10 months ago

Nuveen Preferred and Income Term Fund Announces Shareholder Proposal

BUILD-A-BEAR CELEBRATES VALENTINE'S DAY WITH PAW-SOME SELECTION OF GIFTS STUFFED WITH LOVE

PR Newswire

10 months ago

BUILD-A-BEAR CELEBRATES VALENTINE'S DAY WITH PAW-SOME SELECTION OF GIFTS STUFFED WITH LOVE

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

GlobeNewswire

10 months ago

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024

InvestorPlace

10 months ago

Financial Frontrunners: 3 Stocks Where the Big Money Is Moving in 2024

Insider Stock Buying Reaches US$970.4k On Southern First Bancshares

Simply Wall St.

10 months ago

Insider Stock Buying Reaches US$970.4k On Southern First Bancshares

Pre-Surge Penny Picks: 3 Stocks to Buy Before They Boom

InvestorPlace

a year ago

Pre-Surge Penny Picks: 3 Stocks to Buy Before They Boom

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

GlobeNewswire

a year ago

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Business Wire

a year ago

Forafric Provides Business Update

Business Wire

a year ago

Certain Morgan Stanley Closed-End Funds Declare Year-End Dividends

Business Wire

a year ago

Q1 FY24 Results: Mytheresa Grows +7% in Net Sales in the First Quarter

Are Business Services Stocks Lagging National CineMedia (NCMI) This Year?

Zacks

a year ago

Are Business Services Stocks Lagging National CineMedia (NCMI) This Year?

MVB Bank Named One of American Banker’s 2023 Best Banks to Work For

Business Wire

a year ago

MVB Bank Named One of American Banker’s 2023 Best Banks to Work For

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

GlobeNewswire

a year ago

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

GlobeNewswire

a year ago

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

GlobeNewswire

a year ago

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Zacks

a year ago

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why

Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript

Mytheresa Announces First Quarter of Fiscal Year 2024 Earnings Release and Conference Call

Business Wire

a year ago

Mytheresa Announces First Quarter of Fiscal Year 2024 Earnings Release and Conference Call

GlobeNewswire

a year ago

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Share on Social Networks: